Cardiovascular

FDA releases safety announcement on possible heart failure risk for Mirapex

On Sept. 19, the US Food and Drug Administration released a safety announcement on Mirapex (pramipexole), used to treat Parkinson’s disease and restless legs syndrome, and the possible risk of heart failure. The announcement states, “Because of the study limitations, FDA is not able to determine whether Mirapex increases the risk of heart failure.” The FDA says health care professionals should continue to follow drug-label recommendations when prescribing Mirapex, and that it is continuing to work with the manufacturer to “clarify further the risk of heart failure with Mirapex.” Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares